Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

SUPPLEMENTARY MATERIAL

Table S1: Odds for survival at 90 days. *Legends:* OR = Odds Ratio, CI = Confidence Interval, CND = Chronic Neurological Disease, CVD = Cardiovascular Disease, DM = Diabetes Mellitus, CPD = Chronic Pulmonary Disease, ACEi = Angiotensin-Converting Enzyme-inhibitor, ARB = Angiotensin II Receptor Blocker, ACF = Acute Circulatory Failure, ARF = Acute Respiratory Failure, AKI = Acute Kidney Injury, ICU = Intensive Care Unit.

Table S1: Odds for survival at 90 days.						
Univariate logistic regression				**Multivariable logistic regression**		
Variable	OR	95% CI	*p*-value	OR	95% CI	*p*-value
Immunocompromised	0.21	0.01 - 1.07	0.135			
Liver disease	1.67	0.08 - 17.65	0.678			
Cancer	2.32	0.75 - 6.64	0.123			
CND	0.32	0.02 - 1.73	0.285			
Current smoker	0.95	0.14 - 4.02	0.947			
Gender	1.15	0.66 - 1.99	0.611			
Age	1.08	1.06 - 1.11	**<0.000**	1.08	1.04 - 1.11	**<0.000**
CVD	2.25	1.35 - 3.79	**0.002**	0.72	0.33 - 1.53	0.396
DM	0.97	0.50 - 1.81	0.928			
Asthma	0.76	0.35 - 1.54	0.468			
CPD	3.26	1.57 - 6.71	**0.001**	2.03	0.79 - 5.23	0.139
ACEi/ARB	2.54	1.45 - 4.45	**0.001**	1.94	0.88 - 4.32	0.102
ACF	1.78	1.53 - 2.10	**<0.000**	1.72	1.46 - 2.06	**<0.000**
ARF	1.31	0.96 – 2.00	0.133			
AKI at ICU-admission	3.90	2.31 - 6.67	**<0.000**	3.14	1.66 - 6.00	**0.001**
(Intercept)				0.00	0.00 - 0.002	**<0.000**

OR = Odds Ratio, CI = Confidence Interval, CND = Chronic Neurological Disease, CVD = Cardiovascular Disease, DM = Diabetes Mellitus, CPD = Chronic Pulmonary Disease, ACEi = Angiotensin-Converting Enzyme-inhibitor, ARB = Angiotensin II Receptor Blocker, ACF = Acute Circulatory Failure, ARF = Acute Respiratory Failure, AKI = Acute Kidney Injury, ICU = Intensive Care Unit.

Table S2: Hazard ratio for survival at 30 days. *Legends:* HR = Hazard Ratio, CI = Confidence Interval, CND = Chronic Neurological Disease, CVD = Cardiovascular Disease, DM = Diabetes Mellitus, CPD = Chronic Pulmonary Disease, ACEi = Angiotensin-Converting Enzyme-inhibitor, ARB = Angiotensin II Receptor Blocker, ACF = Acute Circulatory Failure, ARF = Acute Respiratory Failure, AKI = Acute Kidney Injury, ICU = Intensive Care Unit.

Table S2: Hazard ratio for survival at 30 days.						
Univariable Cox regression				**Multivariable Cox regression**		
Variable	HR	95% CI	*p*-value	HR	95% CI	*p*-value
Immunocompromised	0.32	0.05 - 2.30	0.261			
Liver disease	0.85	0.33 - 17.00	0.398			
Cancer	0.97	1.10 - 6.20	**0.023**	2.65	1.11 - 6.36	**0.029**
CND	-0.73	0.07 - 3.50	0.468			
Current smoker	0.15	0.29 - 4.80	0.830			
Gender	0.41	0.90 - 2.60	0.121			
Age	0.07	1.00 - 1.10	**<0.000**	1.05	1.03 - 1.08	**<0.000**
CVD	0.77	1.30 - 3.60	**0.004**	0.96	0.52 - 1.76	0.886
DM	0.12	0.61 - 2.10	0.695			
Asthma	0.08	0.55 - 2.10	0.807			
CPD	1.30	2.00 - 6.40	**<0.000**	2.31	1.25 - 4.25	**0.008**
ACEi/ARB	0.63	1.10 - 3.20	**0.019**	1.37	0.75 - 2.50	0.311
ACF	0.52	1.40 - 2.00	**<0.000**	1.56	1.32 - 1.85	**<0.000**
ARF	0.15	0.83 - 1.60	0.379			
AKI at ICU admission	1.30	2.30 - 6.30	**<0.000**	2.92	1.74 - 4.90	**<0.000**

HR = Hazard Ratio, CI = Confidence Interval, CND = Chronic Neurological Disease, CVD = Cardiovascular Disease, DM = Diabetes Mellitus, CPD = Chronic Pulmonary Disease, ACEi = Angiotensin-Converting Enzyme-inhibitor, ARB = Angiotensin II Receptor Blocker, ACF = Acute Circulatory Failure, ARF = Acute Respiratory Failure, AKI = Acute Kidney Injury, ICU = Intensive Care Unit.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Table S3: Hazard ratio for survival at 90 days. *Legends:* HR = Hazard Ratio, CI = Confidence Interval, CND = Chronic Neurological Disease, CVD = Cardiovascular Disease, DM = Diabetes Mellitus, CPD = Chronic Pulmonary Disease, ACEi = Angiotensin-Converting Enzyme-inhibitor, ARB = Angiotensin II Receptor Blocker, ACF = Acute Circulatory Failure, ARF = Acute Respiratory Failure, AKI = Acute Kidney Injury, ICU = Intensive Care Unit.

Table S3: Hazard ratio for survival at 90 days.						
Univariable Cox regression				**Multivariable Cox regression**		
Variable	HR	95% CI	*p*-value	HR	95% CI	*p*-value
Immunocompromised	0.24	0.03 - 1.70	0.160			
Liver disease	1.80	0.25 - 13.00	0.557			
Cancer	2.10	0.90 - 4.80	**0.086**	2.07	0.88 - 4.88	0.095
CND	0.37	0.05 - 2.60	0.317			
Current smoker	0.92	0.22 - 3.70	0.902			
Gender	1.20	0.74 - 1.90	0.472			
Age	1.10	1.00 - 1.10	**<0.000**	1.05	1.03 - 1.08	**<0.000**
CVD	2.10	1.30 - 3.20	**0.002**	0.85	0.50 - 1.46	0.558
DM	0.99	0.56 - 1.70	0.964			
Asthma	0.81	0.42 - 1.60	0.527			
CPD	2.90	1.70 - 5.10	**<0.000**	2.09	1.18 - 3.70	**0.012**
ACEi/ARB	2.20	1.40 - 3.50	**<0.000**	1.78	1.05 - 3.01	**0.032**
ACF	1.70	1.40 - 1.90	**<0.000**	1.56	1.35 - 1.80	**<0.000**
ARF	1.30	0.91 - 1.80	0.159			
AKI at ICU admission	3.40	2.20 - 5.30	**<0.000**	2.66	1.69 - 4.19	**<0.000**

HR = Hazard Ratio, CI = Confidence Interval, CND = Chronic Neurological Disease, CVD = Cardiovascular Disease, DM = Diabetes Mellitus, CPD = Chronic Pulmonary Disease, ACEi = Angiotensin-Converting Enzyme-inhibitor, ARB = Angiotensin II Receptor Blocker, ACF = Acute Circulatory Failure, ARF = Acute Respiratory Failure, AKI = Acute Kidney Injury, ICU = Intensive Care Unit.

Table S4: Comparison of AKI definitions and staging criteria. *Legends:* AKI = Acute Kidney Injury, KDIGO = Kidney Disease: Improving Global Outcomes, RIFLE = Risk, Injury, Failure, Loss, End-stage kidney disease, SAPS II = Simplified Acute Physiology Score II, SCr = Serum Creatinine, GFR = Glomerular Filtration Rate, UO = Urine Output, BUN = Blood Urea Nitrogen, RRT = Renal Replacement Therapy, h = hours.

Table S4: Comparison of AKI definitions and staging criteria.							
KDIGO		**RIFLE**			**Renal SAPS II**		
Stage	**SCr[a]**	**Class**	**SCr or GFR**	**UO[b]**	**Score**	**UO/24 h**	**BUN**
					0	>1000 ml	<10 mmol/L
1	1.5-1.9x baseline or >26.5 µmol/L increase	Risk	SCr increase 1.5x baseline or eGFR decrease ≥25%	<0.5ml/kg/h for 6 h			
2	2.0-2.9x baseline	Injury	SCr increase 2.0x baseline or eGFR decrease ≥50%	<0.5 ml/kg/h for 12 h (<840 ml/24 h[c])	4	500-999 ml	
					6		10-29.9 mmol/L
3	≥3.0x baseline or ≥4 mg/dl (= 353.7 µmol/L) increase or initiation of RRT	Failure	SCr increase ≥3.0x baseline or ≥4 mg/dl (= 353.7 µmol/L) or GFR decrease ≥75%	<0.3 ml/kg/h for 24 h (<504 ml/24 h[c]) or anuria for 12 hours.	10		>30 mmol/L
					11	<500 ml	

[a]SCr-increase within 48 hours.

[b]UO criteria are shared by KDIGO and RIFLE.

[c]Standardized for a patient with a weight of 70 kg.

AKI = Acute Kidney Injury, KDIGO: Kidney Disease: Improving Global Outcomes, RIFLE: Risk, Injury, Failure, Loss, End-stage kidney disease, SAPS II = Simplified Acute Physiology Score II, SCr = Serum Creatinine, GFR = Glomerular Filtration Rate, UO = Urine Output, BUN = Blood Urea Nitrogen, RRT = Renal Replacement Therapy, h = hours.